Title : Comparison of several developed new Vaccines against COVID 19
Abstract:
During recent years we have witnessed numerous occurrences of viral infectious diseases such as Ebola, MERS, SARS, and recently COVID-19 with a drastic negative effect on human health. Following the outbreak of the COVID-19 pandemic, it has been declared a public health emergency of international concern by the World Health Organization. The causative agent of this infection would be able to transmit via contact with contaminated secretions of infected people, or close contact with a cough or sneeze. Prompt development and comprehensive investigations about the production of an efficacious vaccine against the SARS-CoV-2 have been performed in some countries, but rigorous studies are required to determine the safety and potency of candidate vaccines. SARS-CoV-2 vaccines are being developed using several different platforms. Some of these are traditional approaches, such as an inactivated virus or live attenuated virus platforms, some are newer approaches, such as recombinant proteins and vector vaccines, and some have never been previously employed in a licensed vaccine, such as RNA and DNA vaccines. Also, following availability and widespread uptake of SARS-CoV-2 vaccines, efficacy issues that were not addressed in clinical trials will need to be evaluated, including the duration of protection and the potential need for additional doses, effectiveness in subpopulations not included in trials, and impact on community transmission. Also, in my country some new vaccines were produced as a new effective vaccine by several Research Institutes as first time in Iran. In this lecture, some COVID-19 vaccines will be discussed for effectiveness, safety, protection and efficacy in sensitive and high risk population.
